311 related articles for article (PubMed ID: 34104542)
1. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients.
Machiraju D; Wiecken M; Lang N; Hülsmeyer I; Roth J; Schank TE; Eurich R; Halama N; Enk A; Hassel JC
Oncoimmunology; 2021 May; 10(1):1926762. PubMed ID: 34104542
[TBL] [Abstract][Full Text] [Related]
2. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
3. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
4. Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma.
Machiraju D; Schäfer S; Beckhove P; Roth J; Schulz C; Hassel JC
Front Med (Lausanne); 2023; 10():1117816. PubMed ID: 36756176
[TBL] [Abstract][Full Text] [Related]
5. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
[TBL] [Abstract][Full Text] [Related]
6. CD137
Gelibter A; Asquino A; Strigari L; Zizzari IG; Tuosto L; Scirocchi F; Pace A; Siringo M; Tramontano E; Bianchini S; Bellati F; Botticelli A; Paoli D; Santini D; Nuti M; Rughetti A; Napoletano C
J Transl Med; 2024 Apr; 22(1):329. PubMed ID: 38570798
[TBL] [Abstract][Full Text] [Related]
7. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
[TBL] [Abstract][Full Text] [Related]
8. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Co-Inhibitory Receptor (Co-IR) Expression on T Cells and Soluble Proteins in Rheumatoid Arthritis.
Wang CM; Jan Wu YJ; Huang LY; Zheng JW; Chen JY
Cells; 2024 Feb; 13(5):. PubMed ID: 38474367
[TBL] [Abstract][Full Text] [Related]
10. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
12. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
Front Immunol; 2018; 9():1613. PubMed ID: 30123214
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
15. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
[TBL] [Abstract][Full Text] [Related]
16. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
17. Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients.
Wu Y; Guo H; Yue J; Xu P
J Immunol Res; 2022; 2022():9101912. PubMed ID: 36479137
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
20. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease.
Hadley T; Gillespie S; Espinoza H; Prince J; Gronbaek H; Chandrakasan S; Kuguthasan S; Kolachala VL; Gupta NA
Autoimmunity; 2020 Aug; 53(5):253-260. PubMed ID: 32370568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
